5-Amino-1MQ Oral vs Injection: What Research Shows

Why is 5-Amino-1MQ not actually a peptide?

5-Amino-1MQ, or 5-amino-1-methylquinolinium, is often listed beside research peptides such as BPC-157, Ipamorelin, and Semax. That catalog placement has created a persistent misconception about how the compound behaves when taken orally.

5-Amino-1MQ is a small molecule with a molecular mass of about 159 daltons and a quinolinium ring structure. It has no peptide bonds for pepsin, trypsin, or chymotrypsin to cut. By comparison, BPC-157 is approximately 1,419 daltons, while insulin is roughly 5,800 daltons.

This distinction changes the oral-delivery question. Researchers should ask whether 5-Amino-1MQ crosses the intestinal wall, whether transporters pump it back into the gut, how much reaches systemic circulation, and whether first-pass metabolism changes exposure. The absence of peptide bonds removes the proteolytic-digestion objection; it does not prove that every oral dose reaches circulation unchanged.

How does 5-Amino-1MQ inhibit NNMT?

5-Amino-1MQ is studied as a selective inhibitor of nicotinamide N-methyltransferase (NNMT). NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide. Nicotinamide is also a precursor used to synthesize NAD+, which supports sirtuin activity, mitochondrial function, and cellular energy metabolism.

A 2014 Nature study found that reducing NNMT activity in mouse adipose and liver tissue protected against diet-induced obesity while increasing adipose NAD+ and SAM levels without changing food intake. A 2018 preclinical study introducing 5-Amino-1MQ reported a 7% reduction in body mass and a 30% reduction in adipocyte volume in diet-induced obese mice over 11 days, without caloric restriction.

A 2024 mouse study also reported improved grip strength after NNMT inhibition, with a larger improvement when inhibition was paired with exercise. These findings remain preclinical and do not establish human efficacy.

What does the oral bioavailability research show?

A 2021 validated rat pharmacokinetic study reported 38.4% absolute oral bioavailability for 5-Amino-1MQ. Researchers compared oral and intravenous administration, measured plasma concentrations with a validated LC-MS/MS method, and calculated exposure using area under the concentration-time curve.

• Oral peak plasma concentration: approximately 2,252 ng/mL
• Absolute oral bioavailability: 38.4%
• Oral terminal half-life: approximately 6.9 hours
• Intravenous terminal half-life: approximately 3.8 hours
• Intravenous bioavailability: 100% by definition as the reference route

The longer terminal half-life after oral administration can reflect absorption continuing while elimination is occurring: a phenomenon sometimes described as absorption-limited or “flip-flop” kinetics. It does not necessarily mean the molecule is intrinsically cleared more slowly after oral use. The article points to the bioavailability glossary definition and the broader half-life and bioavailability research guide for context.

What do intestinal permeability studies tell us?

Before efficacy experiments, researchers screened 5-Amino-1MQ with assays commonly used to estimate whether a candidate can cross intestinal barriers. In Caco-2 testing, the reported apparent permeability was 34.2 × 10⁻⁶ cm/s in the absorptive direction, a result consistent with high permeability in this model.

The reported efflux ratio was 1.33. Ratios below 2 are commonly interpreted as showing limited transporter-mediated efflux under the conditions of the assay. The compound also passed a parallel artificial membrane permeability assay.

These tests support membrane permeability and are consistent with the later rat oral-bioavailability result. They do not establish human absorption, optimal formulation, safety, or efficacy.

Why did the efficacy studies use injections?

The published fat-mass, adipocyte, metabolic-marker, and muscle-function experiments used injected 5-Amino-1MQ. That fact shows which route produced controlled exposure in those rodent experiments; it is not a direct finding that oral delivery failed.

Injection is common in small-animal research because it gives investigators precise control over dose and timing. The oral route was not compared against injection for efficacy in those studies. The pharmacokinetic research measured exposure and half-life, not fat loss, strength, or other clinical outcomes.

It is therefore reasonable to say that injected 5-Amino-1MQ has direct preclinical efficacy data and that oral 5-Amino-1MQ has preclinical absorption data. It is not reasonable to claim that equivalent oral and injected exposures have already been proven to produce identical outcomes.

Are there any human trials of 5-Amino-1MQ?

No published human clinical trial has established the pharmacokinetics, safety, or efficacy of 5-Amino-1MQ through either route. The available evidence is based on laboratory assays and animal studies.

Human research does support the relevance of NNMT as a metabolic target. One study involving 199 surgical patients reported approximately twice the adipose NNMT expression in participants with type 2 diabetes compared with insulin-sensitive controls. NNMT expression was inversely associated with insulin sensitivity, and it decreased after exercise intervention and bariatric surgery.

This evidence supports studying NNMT biology. It does not prove that 5-Amino-1MQ is safe or effective in humans, nor does it resolve the oral-versus-injection comparison.

How do oral and injected 5-Amino-1MQ compare?

Injection delivers a greater fraction of a dose into circulation, while oral administration has measured (though incomplete) absorption in rats. No head-to-head human evidence identifies a superior route, dose, schedule, or risk profile.

Community-reported amounts for oral and injectable products are anecdotal and vary widely. They should not be mistaken for validated human dosing guidance.

What testing should researchers look for when sourcing 5-Amino-1MQ?

Because 5-Amino-1MQ has a defined small-molecule structure, documentation should verify identity rather than merely present a generic purity number. Useful documentation can include mass-spectrometry identity confirmation, the observed molecular mass, and quantitative HPLC purity. Products intended for sterile laboratory workflows require route-appropriate sterility and endotoxin documentation.

• Identity: mass spectrometry consistent with the declared compound
• Purity: quantitative HPLC results with the chromatogram and method available
• Quantity: evidence that the labeled amount matches the tested sample
• Sterile formats: relevant sterility and bacterial-endotoxin testing
• Traceability: lot numbers that connect the product to its report

The listed research text specifies using the COA Verification Guide to review laboratory documents, compare the approved research vendor directory, and consult the body-composition research guide for broader context.

Research limitations and practical conclusion

The most supportable conclusion is narrower than many marketing comparisons suggest:

• 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide.
• Rat pharmacokinetic data show measurable oral absorption and 38.4% absolute oral bioavailability.
• Injected administration was used in the published rodent efficacy studies.
• No published human trial validates either route or compares them head to head.
• Bioavailability, efficacy, and safety are separate questions; evidence for one does not automatically answer the others.

For a complete compound overview, see the 5-Amino-1MQ encyclopedia entry.

Published research and further reading

1. NNMT regulation of adipose energy metabolism, NAD+, and SAM (PubMed search)
2. 5-Amino-1MQ and membrane-permeable NNMT inhibitors (PubMed search)
3. Validated 5-Amino-1MQ pharmacokinetic and bioavailability research (PubMed search)
4. NNMT inhibition, exercise, and grip strength in aged mice (PubMed search)
5. Human adipose NNMT expression and insulin sensitivity (PubMed search)